The Evolving Immuno-oncology Landscape in Advanced Lung Cancer: First-line Treatment of Non-small Cell Lung Cancer

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2019 Sep 10

PMID 31497071

Citations 33

Authors

Jia Li Low

Robert J Walsh

Yvonne Ang

Gloria Chan

Ross A Soo

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the most common cancer and leading cause of cancer death. While targeted therapies have redefined treatment options for non-small cell lung carcinoma (NSCLC) with genetic aberrations such as epidermal growth factor and anaplastic lymphoma kinase, many patients do not harbour these oncogenic drivers. Cancer immunology has enabled the development of immune modulators that has dramatically altered the therapeutic landscape of advanced NSCLC. The success of immune-checkpoint inhibitors in pretreated NSCLC has led to the conduct of multiple studies exploring their role in the first-line setting. This article provides an overview of the evolving landscape of immune-checkpoint inhibitors with a focus on the programmed cell-death 1 (PD-1; pembrolizumab, nivolumab) and programmed cell-death ligand 1 (PD-L1; atezolizumab, durvalumab, avelumab) immune-checkpoint inhibitors as single agent or in combination with either chemotherapy or with another immune-checkpoint inhibitor in the treatment of NSCLC, the challenges faced, as well as future perspectives.

Citing Articles

Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC.

Rolfo C, Greillier L, Veillon R, Badin F, Ghiringhelli F, Isambert N JTO Clin Res Rep. 2024; 6(1):100748.

PMID: 39717667 PMC: 11665357. DOI: 10.1016/j.jtocrr.2024.100748.

Chu D, Chen L, Li W, Zhang H Clin Exp Med. 2024; 24(1):104.

PMID: 38761234 PMC: 11102376. DOI: 10.1007/s10238-024-01319-x.

A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.

Dai T, Sun H, Liban T, Vicente-Suarez I, Zhang B, Song Y Sci Rep. 2024; 14(1):10661.

PMID: 38724599 PMC: 11082181. DOI: 10.1038/s41598-024-61477-6.

BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3.

Reggiani F, Talarico G, Gobbi G, Sauta E, Torricelli F, Manicardi V Nat Commun. 2024; 15(1):2567.

PMID: 38519469 PMC: 10960013. DOI: 10.1038/s41467-024-46778-8.

Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review.

Cheng M, Shao Y, Li L, Jiang M, Song Z BMC Cancer. 2024; 24(1):312.

PMID: 38448878 PMC: 10916025. DOI: 10.1186/s12885-024-12043-w.

References

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Sharpe A, Freeman G . The B7-CD28 superfamily. Nat Rev Immunol. 2002; 2(2):116-26. DOI: 10.1038/nri727. View

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002; 99(19):12293-7. PMC: 129438. DOI: 10.1073/pnas.192461099. View

Demaria S, Kawashima N, Yang A, Devitt M, Babb J, Allison J . Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005; 11(2 Pt 1):728-34. View

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z . CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008; 322(5899):271-5. DOI: 10.1126/science.1160062. View

Peggs K, Quezada S, Chambers C, Korman A, Allison J . Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009; 206(8):1717-25. PMC: 2722174. DOI: 10.1084/jem.20082492. View

Verbrugge I, Hagekyriakou J, Sharp L, Galli M, West A, McLaughlin N . Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012; 72(13):3163-74. DOI: 10.1158/0008-5472.CAN-12-0210. View

Bracci L, Schiavoni G, Sistigu A, Belardelli F . Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2013; 21(1):15-25. PMC: 3857622. DOI: 10.1038/cdd.2013.67. View

10.

Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T . A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013; 14(12):1212-8. DOI: 10.1038/ni.2762. View

11.

Reck M, Kaiser R, Mellemgaard A, Douillard J, Orlov S, Krzakowski M . Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2):143-55. DOI: 10.1016/S1470-2045(13)70586-2. View

12.

Sundar R, Soong R, Cho B, Brahmer J, Soo R . Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer. 2014; 85(2):101-9. PMC: 4332778. DOI: 10.1016/j.lungcan.2014.05.005. View

13.

Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Goksel T . Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384(9944):665-73. DOI: 10.1016/S0140-6736(14)60845-X. View

14.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

15.

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

16.

Mahoney K, Rennert P, Freeman G . Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015; 14(8):561-84. DOI: 10.1038/nrd4591. View

17.

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

18.

Smyth M, Ngiow S, Ribas A, Teng M . Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2015; 13(3):143-58. DOI: 10.1038/nrclinonc.2015.209. View

19.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

20.

Antonia S, Goldberg S, Balmanoukian A, Chaft J, Sanborn R, Gupta A . Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016; 17(3):299-308. PMC: 5500167. DOI: 10.1016/S1470-2045(15)00544-6. View